Neo-/Adjuvant Phase III Trial to Compare Intense Dose-dense Chemotherapy to Tailored Dose-dense Chemotherapy in Patients With High-risk Early Breast Cancer (GAIN-2)

Trial Profile

Neo-/Adjuvant Phase III Trial to Compare Intense Dose-dense Chemotherapy to Tailored Dose-dense Chemotherapy in Patients With High-risk Early Breast Cancer (GAIN-2)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 11 Aug 2017

At a glance

  • Drugs Cyclophosphamide (Primary) ; Epirubicin (Primary) ; Paclitaxel (Primary) ; Docetaxel; Trastuzumab
  • Indications Early breast cancer
  • Focus Biomarker; Pharmacogenomic; Therapeutic Use
  • Acronyms GAIN-2
  • Most Recent Events

    • 10 Jul 2017 Status changed from recruiting to active, no longer recruiting.
    • 10 Jun 2017 Biomarkers information updated
    • 12 Dec 2015 Interim results (second safety analysis) presented at the 38th Annual San Antonio Breast Cancer Symposium (n = 1473).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top